Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  
 449 Diseases   58 Trials   58 Trials   3605 News 


«12...1112131415161718192021...2425»
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Enrollment open, Enrollment change, Trial primary completion date:  Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) -  Oct 14, 2016   
    P2,  N=25, Recruiting, 
    Trial primary completion date: Jan 2015 --> Apr 2017 Not yet recruiting --> Recruiting | N=10 --> 25 | Trial primary completion date: May 2017 --> May 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) -  Oct 11, 2016   
    P2,  N=340, Active, not recruiting, 
    Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  humanised dinutuximab (Hu14.18K322A) / Essential Pharma
    Enrollment change, Metastases:  Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) -  Sep 7, 2016   
    P2,  N=210, Recruiting, 
    Not yet recruiting --> Recruiting N=150 --> 210
  • ||||||||||  humanised dinutuximab (Hu14.18K322A) / Essential Pharma
    Trial primary completion date, Metastases:  Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) -  Aug 8, 2016   
    P2,  N=150, Recruiting, 
    Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Sep 2018 --> Jan 2021
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) -  Aug 8, 2016   
    P2,  N=40, Recruiting, 
    Trial primary completion date: Sep 2018 --> Jan 2021 Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment open, Trial initiation date, Trial primary completion date:  Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) -  Jul 28, 2016   
    P2,  N=188, Recruiting, 
    Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020
  • ||||||||||  SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion:  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) -  Jul 26, 2016   
    P1,  N=9, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020 Active, not recruiting --> Completed
  • ||||||||||  temozolomide / Generic mfg.
    Enrollment closed, Enrollment change, Immunomodulating:  GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) -  Jul 26, 2016   
    P1,  N=16, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 16
  • ||||||||||  Sitoiganap (ERC1671) / Epitopoietic Research Corp
    Trial primary completion date:  ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) -  Jun 30, 2016   
    P2,  N=84, Recruiting, 
    Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jun 2021 --> Jan 2022 Trial primary completion date: Mar 2016 --> Mar 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
    Enrollment open, Trial initiation date, Trial primary completion date, IO biomarker:  VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Jun 29, 2016   
    P2,  N=108, Recruiting, 
    Trial primary completion date: Mar 2016 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Sep 2019 --> Mar 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial initiation date, IO biomarker:  The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) -  Jun 10, 2016   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Sep 2019 --> Mar 2019 Initiation date: Sep 2015 --> Jun 2014
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial completion, Trial primary completion date:  Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) -  May 24, 2016   
    P1,  N=37, Completed, 
    Initiation date: Sep 2015 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jan 2016
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
    Enrollment open, Metastases:  Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) -  May 16, 2016   
    P2,  N=27, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date, Immunomodulating:  GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) -  May 5, 2016   
    P4,  N=200, Recruiting, 
    Trial primary completion date: Aug 2015 --> Apr 2007 Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  humanised dinutuximab (Hu14.18K322A) / Essential Pharma
    Enrollment change, Metastases:  Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) -  Apr 11, 2016   
    P2,  N=150, Recruiting, 
    Trial primary completion date: Oct 2015 --> Feb 2019 N=42 --> 150
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
    New P2 trial, Metastases:  Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) -  Mar 9, 2016   
    P2,  N=27, Not yet recruiting, 
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Mar 5, 2016   
    P2,  N=70, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017